The Filing Cabinet logo

The Filing Cabinet

Archives
March 25, 2026

⚖️ CPSC issues 5 recalls this week; bike helmets, ranges, steamers flagged

The Consumer Product Safety Commission issued five recalls this week spanning bike helmets that failed impact testing, gas ranges with burn hazards, and infant walkers with fall risks. The Aisstxoer adult bike helmet recall addresses impact protection failures, while Frigidaire gas ranges were...

The Regulatory Pulse | Wednesday, March 25, 2026

This week's 377 regulatory actions span critical consumer safety recalls and significant air quality determinations across multiple agencies. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

THE REGULATORY PULSE

Wednesday, March 25, 2026

from The Filing Cabinet · Read on web

We tracked 377 regulatory actions this week. Here's what stood out.
76 FDA193 Regulatory100 Clinical8 Safety

This week's regulatory activity at a glance.

The Consumer Product Safety Commission issued <strong>five recalls</strong> this week spanning bike helmets that failed impact testing, gas ranges with burn hazards, and infant walkers with fall risks. The <strong>Aisstxoer adult bike helmet recall</strong> addresses impact protection failures, while <strong>Frigidaire gas ranges</strong> were pulled for burn hazards alongside <strong>Wagner power steamers</strong> and <strong>BUILT LUUM tumblers</strong> with defective lids. <strong>Goregent infant walkers</strong> round out the week's enforcement actions for noncompliance with federal safety standards on fall prevention.

FEDERAL REGISTER15 items
REGULATORY

Determination of Attainment by the Attainment Date But for International Emissions for the 2015 Ozone National Ambient Air Quality Standards; Phoenix-Mesa Nonattainment Area, Arizona

EPA has issued a determination that the <strong>Phoenix-Mesa nonattainment area</strong> would have attained the <strong>2015 ozone NAAQS</strong> by the attainment date but for international emissions. This finding addresses ozone standard compliance in the Arizona region.

REGULATORY

Approval of Clean Air Plans; San Joaquin Valley, California; Contingency Measures for 1997 Ozone Standards

EPA has approved contingency measures submitted by <strong>San Joaquin Valley, California</strong> for the <strong>1997 ozone standards</strong>. The approval incorporates additional air quality plan provisions into the state implementation plan.

REGULATORY

Air Plan Approval; Texas; Reasonably Available Control Technology in the Dallas-Fort Worth Ozone Nonattainment Area

EPA has approved air plan provisions implementing <strong>reasonably available control technology (RACT)</strong> requirements in the <strong>Dallas-Fort Worth ozone nonattainment area</strong>. The action finalizes Texas state implementation plan revisions for ozone precursor controls.

—EPA approves Ohio air quality plan for volatile organic compound reduction
—EPA approves air quality plan revisions for Mojave Desert district
—EPA approves New Hampshire air plan for Hutchinson Sealing Systems VOC controls
—EPA approves Texas air quality plan for Houston-Galveston-Brazoria ozone control
—FDIC clarifies deposit insurance rules for U.S. bank branches in Pacific islands
—FAA renames seven restricted airspace zones at Fort Moore, Georgia
—FAA renames three military airspace restrictions at Fort Novosel, Alabama
—SEC proposes framework classifying crypto assets under federal securities laws
CLINICAL TRIALS2 items
CLINICALABBV

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) , PHASE3

<strong>AbbVie (ABBV)</strong> has completed the <strong>TRANSFORM-1 Phase 3</strong> clinical trial evaluating <strong>navitoclax in combination with ruxolitinib</strong> versus ruxolitinib alone in subjects with <strong>myelofibrosis</strong>. The randomized, double-blind, placebo-controlled study has reached completion status.

ABBV
CLINICALPFE

A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) , PHASE2, PHASE3

<strong>Pfizer (PFE)</strong> has completed a long-term, open-label follow-up <strong>Phase 2/Phase 3</strong> study of <strong>tofacitinib</strong> for treatment of <strong>juvenile idiopathic arthritis (JIA)</strong>. The trial assessed extended safety and efficacy of the therapy in pediatric patients.

PFE
PRODUCT SAFETY5 items
RECALL

Product Recall: Aisstxoer Adult Bike Helmets

<strong>Aisstxoer Adult Bike Helmets</strong> are subject to a product recall. No additional details regarding the recall classification, affected unit count, or hazard type are available in the source material.

RECALL

Product Recall: Frigidaire Gas Ranges

<strong>Frigidaire Gas Ranges</strong> are subject to a product recall. No additional details regarding the recall classification, affected unit count, or hazard type are available in the source material.

RECALL

Product Recall: Goregent Infant Walkers

<strong>Goregent Infant Walkers</strong> are subject to a product recall. No additional details regarding the recall classification, affected unit count, or hazard type are available in the source material.

—CPSC recalls BUILT LUUM Tumblers for burn hazard from lid detachment
—CPSC recalls Wagner 900 Series Power Steamers for burn hazard
EPA ACTIONS3 items
—EPA settles Safe Drinking Water Act violations with Peggs Water Company
—EPA settles Safe Drinking Water Act violations with Osage County RWD #21
—EPA settles TSCA violation with CIMCO Management for $2,500
View all Regulatory Pulse issues (March 25, 2026)

Know someone in regulated industries?

Share The Regulatory Pulse with them.

Forward to a FriendShare on X

The Filing Cabinet

Not professional advice. Not even close.

X · Bluesky · Threads

Add regulatorypulse@mail.thefilingcabinet.news to your contacts for best delivery.

Unsubscribe

Don't miss what's next. Subscribe to The Filing Cabinet:
Powered by Buttondown, the easiest way to start and grow your newsletter.